These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6665494)

  • 1. Changes of the cellular immunity tests during the evolution of Hodgkin's disease.
    Răileanu-Moţoiu I; Dumitrescu A; Costescu M; Mocanu N; Berceanu S
    Med Interne; 1983; 21(3):203-15. PubMed ID: 6665494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease].
    Pluzańska A
    Acta Haematol Pol; 1978; 9(1):37-44. PubMed ID: 307325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferritin-bearing lymphocytes in Hodgkin's disease.
    Koprivová H; Hermanská Z; Novák F; Blehová Z; Dienstbier Z
    Neoplasma; 1986; 33(1):63-9. PubMed ID: 3515213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of splenectomy, radiotherapy and chemotherapy on the immune response in Hodgkin's disease.
    Van Rijswijk RE; Sybesma JP; Kuipers JT; Zegers BJ; Borst-Eilers E
    Neth J Med; 1976; 19(4-5):201-8. PubMed ID: 980188
    [No Abstract]   [Full Text] [Related]  

  • 6. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
    Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
    Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary evaluation of immunotherapy in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Karpowicz M; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Małkowska-Zwierz W; Pawelski S
    Arch Immunol Ther Exp (Warsz); 1981; 29(6):739-55. PubMed ID: 7349093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cellular immune response and concentrations of serum immunoglobulins in patients with Hodgkin's disease (author's transl)].
    Stefanits K; Kuhn E; Ambrus M; Csere T
    Strahlentherapie; 1979 May; 155(5):335-40. PubMed ID: 442117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinguishing features of the immunology of Hodgkin's disease in children.
    Tan CT; De Sousa M; Good RA
    Cancer Treat Rep; 1982 Apr; 66(4):969-75. PubMed ID: 7074657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune status of untreated patients with Hodgkin's disease and prognosis.
    Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H
    Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dynamics of the immunological indices in lymphogranulomatosis following splenectomy and radiation therapy].
    Ankudinov VA; Asliaev LA; Khvorostenko MI; Krugovov BA; Kosse VA
    Vopr Onkol; 1981; 27(4):26-31. PubMed ID: 7233871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.
    Passwell J; Levanon M; Davidsohn J; Ramot B
    Clin Exp Immunol; 1983 Jan; 51(1):61-8. PubMed ID: 6572580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blastogenic transformation of lymphocytes following phytohaemagglutinin treatment in vitro in malignant lymphomas. I. Hodgkin's disease. (Correlation with immunity response of the cellular type and with the clinical status).
    Libánský J; Lukásová M; Pinosová I
    Neoplasma; 1973; 20(1):51-60. PubMed ID: 4702205
    [No Abstract]   [Full Text] [Related]  

  • 14. Zinc status and cellular immunity in pediatric Hodgkin's disease.
    Cavdar AO; Babacan E; Ertem U; Gözdasoğlu S; Arcasoy A
    Prog Clin Biol Res; 1983; 129():207-20. PubMed ID: 6657703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunity and hypersensitivity in Hodgkin's lymphoma].
    Leoni P; Marchegiani G; Montillo M; Centurioni R; Montroni M; Danieli G
    Minerva Med; 1982 May; 73(20):1361-9. PubMed ID: 6210855
    [No Abstract]   [Full Text] [Related]  

  • 16. Decreased "active" rosette-forming cells during remission in Hodgkin's disease.
    Lang JM; Bigel P; Oberling F; Mayer S
    Biomedicine; 1978 May; 29(3):83-4. PubMed ID: 687748
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of radiochemotherapy and splenectomy on lymphoid subclasses in patients with Hodgkin's lymphoma in complete remission].
    Leoni P; Montroni M; Montillo M; Salvi A; Centurioni R; Fanciulli E
    G Clin Med; 1981 Oct; 62(10):685-92. PubMed ID: 6977469
    [No Abstract]   [Full Text] [Related]  

  • 18. [Role of splenectomy in impairing lymphocyte elimination in patients with lymphogranulomatosis].
    Kuz'mina EG; Bogatyreva TI; Baĭsogolov GD; Iarilin AA
    Vopr Onkol; 1986; 32(8):65-8. PubMed ID: 3765511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunity in Hodgkin's lymphoma].
    Danieli G; Montroni M; Leoni P; Magelli L; Totti S
    G Clin Med; 1975; 56(1):39-56. PubMed ID: 770222
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune condition in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Traczyk Z; Pawelski S; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Karpowicz M; Małkowska-Zwierz W
    Arch Immunol Ther Exp (Warsz); 1980; 28(1):153-60. PubMed ID: 6968189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.